Table 1 –
Characteristics of 98 prostate cancer patients treated with radical prostatectomy but retrospectively evaluated as candidates for focal therapy with primary definition of extensive disease. All values are median (interquartile range) or frequency (proportion)
| No Extensive Disease at RP (N=59; 60%) | Extensive Disease at RP (N=39; 40%) | |
|---|---|---|
| Age at diagnostic biopsy (yr) | 57 (52, 63) | 58 (53, 65) |
| Gleason score at diagnostic biopsy | ||
| 6 | 42 (71%) | 14 (36%) |
| 3+4 | 17 (29%) | 25 (64%) |
| Percentage of positive cores at diagnostic biopsy | 13.3 (7.7, 25.0) | 16.7 (8.3, 30.8) |
| Clinical stage | ||
| T1c | 52 (88%) | 32 (82%) |
| T2a | 7 (12%) | 7 (18%) |
| Kattan nomogram score* | 8.7 (8.0, 15.1) | 14.9 (12.1, 19.6) |
| Prostate volume on MRI (cm3) | 35.2 (26.8, 48.0) | 33.0 (25.6, 38.2) |
| Pre-RP PSA level (ng/ml) | 4.5 (3.3, 6.2) | 5.6 (4.1, 7.6) |
| Gleason score at RP | ||
| 6 | 26 (44%) | 0 |
| 3+4 | 33 (56%) | 39 (100%) |
| Pathologic stage at RP | ||
| T2 | 59 (100%) | 22 (56%) |
| T3a | 0 | 14 (36%) |
| T3b | 0 | 2 (5%) |
| T4 | 0 | 1 (2.6%) |
| Gleason pattern 4/5 in bilateral lobes | 0 | 32 (82%) |
| Tumor volume of Gleason pattern 4/5 in biopsy negative lobe (cm3) (N=32) | - | 0.06 (0.02,0.14) |
| Dominant tumor volume with Gleason pattern 4 or 5 in biopsy negative lobe (cm3) (N=32) | - | 0.2 (0.1, 0.5) |
| Gleason score 3+4 (cm3) (N=26) | - | 0.2 (0.2, 0.5) |
| Gleason score 4+3 (cm3) (N=6) | - | 0.1 (0.1, 0.4) |
| Extraprostatic extension | 0 | 17 (44%) |
| Seminal vesicle involvement | 0 | 2 (5.1%) |
| Lymph node invasion | 0 | 1 (2.6%) |
MRI = magnetic resonance imaging; PSA = prostate-specific antigen; RP = radical prostatectomy.
*
The Kattan nomogram score incorporates PSA, clinical stage, and biopsy Gleason score.